BioNTech to Establish Regional Headquarters and mRNA Manufacturing Facility in Singapore

BioNTech SE, the vaccine maker, is designating Singapore as its regional headquarters for South-east Asia and plans to set up a messenger RNA (mRNA) manufacturing facility. The facility will produce Covid-19 vaccines and create at least 80 jobs, including roles in quality control, quality assurance, and management. The expansion plan is supported by Singapore's Economic Development Board (EDB), and BioNTech aims to open its Singapore office and start construction this year, subject to planning approval.

Key Takeaways:

• BioNTech will establish its regional headquarters in Singapore, serving as the hub for South-east Asia.
• The mRNA manufacturing facility will produce Covid-19 vaccines and create at least 80 jobs.
• The facility will be operational in 2023 and will be used to produce a range of novel mRNA vaccines and therapeutics for infectious diseases and cancer.
• The investment in Singapore is valued in the range of hundreds of millions of US dollars.
• The facility will use cutting-edge manufacturing and digital infrastructure and is expected to be a long-term investment in biotech in Singapore.
• BioNTech plans to deliver up to three billion doses of the Covid-19 vaccine this year, with at least 40% going to low- and middle-income countries.

Statistics:

• The Covid-19 vaccine has been administered to over 1 billion people worldwide.
• BioNTech plans to deliver up to three billion doses of the Covid-19 vaccine this year.
• At least 40% of the doses will be supplied to low- and middle-income countries.
• The investment in Singapore is valued in the range of hundreds of millions of US dollars.

Sources:

• BioNTech SE
• Singapore's Economic Development Board (EDB)
• The World Health Organisation